Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of gu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Oddo, Daniele, Sennott, Erin M., Barault, Ludovic, Valtorta, Emanuele, Arena, Sabrina, Cassingena, Andrea, Filiciotto, Genny, Marzolla, Giulia, Elez, Elena, van Geel, Robin M.J.M., Bartolini, Alice, Crisafulli, Giovanni, Boscaro, Valentina, Godfrey, Jason T., Buscarino, Michela, Cancelliere, Carlotta, Linnebacher, Michael, Corti, Giorgio, Truini, Mauro, Siravegna, Giulia, Grasselli, Julieta, Gallicchio, Margherita, Bernards, René, Schellens, Jan H.M., Tabernero, Josep, Engelman, Jeffrey A., Sartore-Bianchi, Andrea, Bardelli, Alberto, Siena, Salvatore, Corcoran, Ryan B., Di Nicolantonio, Federica
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970882/
https://ncbi.nlm.nih.gov/pubmed/27312529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados